The Irritable Bowel Syndrome

A 45 year old businessman presents at your clinic with a 2 year history of recurrent abdominal pain, associated with frequent bouts of diarrhoea. The pain is relieved by defaecation, but there is often a feeling of incomplete evacuation. Between these episodes he is often constipated, with infrequent bowel motions characterised by hard stools. During stressful situations, symptoms get worse and are associated with abdominal bloating and increased flatulence. He researched his problem on the internet and thinks he might have Irritable Bowel Syndrome.peer-reviewe

Review article: the economic impact of the irritable bowel syndrome

Background: Irritable bowel syndrome (IBS) is a chronic functional disorder of the gastrointestinal system affecting a large number of people worldwide. Whilst it has no attributable mortality, it has substantial impact on patients' quality of life (QoL) and is associated with considerable healthcare resource use. Aim: To review the economic impact of IBS, firstly on the individual, secondly on healthcare systems internationally and thirdly to society. Methods: Appropriate databases were searched for relevant papers using the terms: Irritable Bowel Syndrome; IBS; irritable colon; functional bowel/colonic disease; economics; health care/service costs; health expenditure/resources; health care/service utilisation; productivity. Results: Irritable bowel syndrome impacts most substantially on patients' work and social life. Reduction in QoL is such that on average patients would sacrifice between 10 and 15 years of their remaining life expectancy for an immediate cure. Between 15% and 43% of patients pay for remedies. No studies quantify loss of earnings related to IBS. Direct care costs are substantial; 48% of patients incur some costs in any year with annual international estimates per patient of: USA $742–$7547, UK £90–£316, France €567–€862, Canada $259, Germany €791, Norway NOK 2098 (€262) and Iran$92. Minimising extensive diagnostic investigations could generate savings and has been shown as not detrimental to patients. Cost to industry internationally through absenteeism and presenteeism related to IBS is estimated between £400 and £900 per patient annually. Conclusions: costs to patients, healthcare systems and society. Considerable benefit could be obtained from effective interventions

It's all in the name, or is it? The impact of labelling on health state values

Many descriptions of health used in vignettes and condition-specific measures refer to the medical condition. This paper assesses the impact of referring to the medical condition in the descriptions of health states valued by members of the general population. A sample of 241 members of the UK general population each valued 8 health states using time trade-off. All respondents valued essentially the same health states, but for each respondent the descriptions featured either an irritable bowel syndrome label, a cancer label or no label. Regression techniques were used to estimate the impact of each label and experience of the condition on health state values. We find that the inclusion of a cancer label in health state descriptions affects health state values and that the impact is dependent upon the severity of the state. A condition label can affect health state values, but this is dependent upon the specific condition and severity. It is recommended to avoid condition labels in health state descriptions (where possible) to ensure that values are not affected by prior knowledge or preconception of the condition that may distort the health state being valued

The effectiveness and cost-effectiveness of cognitive behavioral therapy administered in group or via the internet for patients with irritable bowel syndrome

Background Irritable Bowel Syndrome (IBS) is a benign but debilitating disorder. It is the most commonly diagnosed gastrointestinal condition and affects between 7-21% of the world’s population. It is characterized by abdominal pain and altered bowel habits. Patients with refractory IBS tend to develop behavioral avoidance that may severely affect life quality and lead to aggravated symptoms. Psychological treatment has emerged as a potent way of treating patients with IBS. Professor Brjánn Ljótsson at Karolinska Institutet has developed a cognitive behavioral treatment protocol specific for IBS. One of the core components in the treatment is exposure to feared stimuli such as specific foods or situations. Four different RCTs have proven the efficacy of the treatment. In randomized controlled trials the goal is to find a potential treatment effect and the setting is normally adjusted to eliminate confounding factors (i.e by careful selection of patients and by utilizing specially trained staff that is supervised during the treatment phase and by providing many examinations or questionnaires to patients). Clinical routine care may often differ from the context of a randomized controlled trial, and it is therefore important to examine the effectiveness of a potentially effective treatment under real world circumstances. When a new and potentially more effective treatment is developed health care managers must decide whether it should be implemented in routine care or not, and one of the important questions concerns the costs for the new treatment in comparison to already implemented methods. Knowledge regarding cost-effectiveness is therefore needed. Aims The general aim of the present thesis is to examine the real-world effectiveness of the exposure-based cognitive behavioral treatment (ECBT) our research group has developed and to evaluate its cost-effectiveness to provide managers in health care with a better foundation for good decisions. Specific aims of this theses were to: a) evaluate the cost-effectiveness from a societal perspective of the exposure component in the ECBT when delivered over the internet (study I), b) evaluate the real-world treatment effectiveness of the ECBT when delivered face-to-face in a group format and to investigate possible predictors of treatment outcome (study II), and to evaluate the real-world effectiveness of the ECBT when delivered over the internet and to replicate an earlier finding that behavioral change predicts symptom-reduction and thus a potential working mechanism of the treatment (study III). Methods Study I randomized 309 self-referred patients to internet-delivered CBT (ICBT) with or without exposure (WE) and examined the costs of the intervention as well as potential cost reductions for society and related them to treatment effects. Study II used data from the electronical medical record at a gastroenterological clinic and compared symptom burden before and after patents went through a group based ECBT face-to-face. The study included 129 patients with refractory IBS. Baseline data was used to try to create a prediction model for treatment outcome. Study III included 309 consecutively recruited patients at the Internet Psychiatry Unit who received a 12-week internet-based ECBT for IBS. The effectiveness of the treatment was calculated at the end of treatment and six months after treatment started. In the study a random intercept cross-lagged panel model was used to investigate the relationship between behavioral change and symptom reduction over time. Results In both effectiveness studies (studies II and III) the patients were significantly improved after treatment and the calculated effect sizes indicated that the treatment effect is large. In study II, 52.7% of the patients had a symptomatic reduction measured with GSRS-IBS of 30% or more which is considered a clinically significant improvement. There was not enough support for the construction of a prediction model based on pre-treatment characteristics that would predict symptomatic improvement. The cost-effectiveness study (study I) showed that the exposure component makes the treatment approximately 20% more expensive, but that the money invested in exposure pays back with almost 6 times the investment in saved expenses from a societal perspective during the six months following the treatment. There is an 84% chance that the ECBT will be more cost-effective than ICBT-WE if society is willing to pay no more for the ECBT than for the ECBT-WE. Finally, in study III, we also found support for the hypothesis that the symptom reduction patients experience after ECBT is related to behavior change during the treatment, prior to the outcome. Conclusion ECBT is highly effective, also under real world circumstances, both when delivered face-to-face and over the internet. The exposure component in the treatment is related to behavior change that in turn predicts treatment outcome, thus pointing to a possible chain of events partly explaining the working mechanism of the treatment. Lastly, we conclude that it is very cost-effective from a societal perspective to include exposure in the treatment since the extra costs are weighed out many times by saved expenses down the road

A randomised controlled trial on hypnotherapy for irritable bowel syndrome: design and methodological challenges (the IMAGINE study)

<p>Abstract</p> <p>Background</p> <p>Irritable Bowel Syndrome (IBS) is a common gastro-intestinal disorder in primary and secondary care, characterised by abdominal pain, discomfort, altered bowel habits and/or symptoms of bloating and distension. In general the efficacy of drug therapies is poor. Hypnotherapy as well as Cognitive Behaviour Therapy and short Psychodynamic Therapy appear to be useful options for patients with refractory IBS in secondary care and are cost-effective, but the evidence is still limited. The IMAGINE-study is therefore designed to assess the overall benefit of hypnotherapy in IBS as well as comparing the efficacy of individual versus group hypnotherapy in treating this condition.</p> <p>Methods/Design</p> <p>The design is a randomised placebo-controlled trial. The study group consists of 354 primary care and secondary care patients (aged 18-65) with IBS (Rome-III criteria). Patients will be randomly allocated to either 6 sessions of individual hypnotherapy, 6 sessions of group hypnotherapy or 6 sessions of educational supportive therapy in a group (placebo), with a follow up of 9 months post treatment for all patients. Ten hospitals and four primary care psychological practices in different parts of The Netherlands will collaborate in this study. The primary efficacy parameter is the responder rate for adequate relief of IBS symptoms. Secondary efficacy parameters are changes in the IBS symptom severity, quality of life, cognitions, psychological complaints, self-efficacy as well as direct and indirect costs of the condition. Hypnotherapy is expected to be more effective than the control therapy, and group hypnotherapy is expected not to be inferior to individual hypnotherapy.</p> <p>Discussion</p> <p>If hypnotherapy is effective and if there is no difference in efficacy between individual and group hypnotherapy, this group form of treatment could be offered to more IBS patients, at lower costs.</p> <p>Trial registration number</p> <p>ISRCTN: <a href="http://www.controlled-trials.com/ISRCTN22888906">ISRCTN22888906</a></p

Effects of FODMAPs and gluten on irritable bowel syndrome- from self-reported symptoms to molecular profiling

Irritable bowel syndrome (IBS) is a complex disorder of gut-brain interactions. The diagnosis of IBS is based on subjective reporting of abdominal pain and altered bowel habits in the absence of any clinical alterations of the gut or other pathological conditions. Dietary regimens for symptom management include a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) diet and a gluten-free diet. However, scientific evidence supporting these dietary recommendations for managing IBS symptoms is weak: trials have been non-blinded and underpowered. While mechanistic understanding and objective markers of response remain scarce. Therefore, the aim of this thesis was to conduct a large double-blind study to investigate the effect of FODMAPs and gluten on symptomatic and molecular data including 16S rRNA analysis of the gut microbiota and metabolomics analyses, both at a group and subgroup (differential response) level. The resulting data served also to assess the accuracy of the Bristol Stool Form Scale (BSFS) used in IBS subtype diagnosis, and thus overcome the lack of objective evaluation of IBS symptoms.Trial data revealed that gluten caused no symptoms and FODMAPs triggered only modest symptoms of IBS, albeit with large inter-individual differences. Subjective reporting according to the BSFS conformed only modestly with stool water content in IBS, warranting caution towards IBS subtyping. FODMAPs increased saccharolytic microbial genera, phenolic-derived metabolites and 3-indolepropionate, but decreased bile acids. The genera Agathobacter, Anaerostipes, Fusicatenibacter, and Bifidobacterium correlated with increased plasma concentrations of phenolic-derived metabolites and 3-indolepropionate, i.e, metabolites related to decreased risk of incident type 2 diabetes and inflammation. Indeed, among FODMAP-related metabolites, only weak correlations to IBS symptoms were detected, as in the case of 3-indolepropionate to abdominal pain and interference with quality of life, warranting further investigation. Gluten displayed a modest effect on metabolites involved in lipid metabolism, including carnitine derivates, an acyl-CoA derivate, a medium-chain fatty acid, and an unknown lipid, but with no interpretable link to health.No molecular markers of a differential response were found, despite a comprehensive exploration with multiple analytical approaches. This could be explained by the absence of baseline variables, such as other omics layers or psychological factors, that could have determined the difference. In summary, the results indicate that gluten does not cause IBS symptoms. Moreover, the minor effect of FODMAPs on IBS symptoms must be weighed against their potential beneficial health effects. While the complexity of IBS likely explains the absence of molecular evidence for differential responses, such data analytical approach has potential where clear benefits of dietary interventions exist. Finally, the use of BSFS should include training for self-assessment, as a tool for subtyping IBS

It's all in the name, or is it? The impact of labelling on health state values

Many descriptions of health used in vignettes and condition-specific measures refer to the medical condition. This paper assesses the impact of referring to the medical condition in the descriptions of health states valued by members of the general population. A sample of 241 members of the UK general population each valued 8 health states using time trade-off. All respondents valued essentially the same health states, but for each respondent the descriptions featured either an irritable bowel syndrome label, a cancer label or no label. Regression techniques were used to estimate the impact of each label and experience of the condition on health state values. We find that the inclusion of a cancer label in health state descriptions affects health state values and that the impact is dependent upon the severity of the state. A condition label can affect health state values, but this is dependent upon the specific condition and severity. It is recommended to avoid condition labels in health state descriptions (where possible) to ensure that values are not affected by prior knowledge or preconception of the condition that may distort the health state being valued

The Efficacy of a Diet Low in Fermentable Oligo-, Di-, Monosaccharides, and Polyols in Irritable Bowel Syndrome Compared to Its "Real-world" Effectiveness: Protocol for a Systematic Review.

BACKGROUND Irritable bowel syndrome (IBS) is associated with various gastrointestinal and nongastrointestinal symptoms and reduced quality of life. A diet low in fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs) is one therapeutic option for IBS. Although the efficacy of the low FODMAP diet has been reported in several systematic reviews, the efficacy-effectiveness gap of the low FODMAP diet has not yet been assessed. OBJECTIVE This systematic review aims to compare the efficacy of the low FODMAP diet from efficacy randomized controlled trials (RCTs) with the effectiveness of studies conducted in "real-world" settings. METHODS RCTs, prospective and retrospective cohort studies, and retrospective audits assessing the low FODMAP diet in adults with IBS will be searched in 4 databases: Embase, MEDLINE, CENTRAL, and CINAHL. Two independent reviewers will perform study selection, data extraction, and risk of bias assessment and assess selected quality aspects from the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) protocol. Outcomes assessed are stool frequency, stool consistency, abdominal pain, overall symptom scores, adequate symptom relief, IBS-specific quality of life, and diet adherence. Data will be summarized with forest plots without summary statistics, tables, and narrative descriptions. RESULTS The search, title and abstract screening, and full-text screening were completed in March 2021, and an updated search was done in May 2022. As of May 2023, data analysis is almost finished, and manuscript writing is in progress. Submission of the manuscript is expected by July 2023. CONCLUSIONS The findings of this systematic review will compare the efficacy of the low FODMAP diet for IBS found in RCTs to the diet's real-world effectiveness. TRIAL REGISTRATION PROSPERO CRD42021278952; https://tinyurl.com/32jk43ev. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/41399

Recent advances in understanding and managing chronic pelvic pain in women with special consideration to endometriosis

Chronic pelvic pain (CPP) in women is defined variably, but for clinical use it is cyclical or non-cyclical pain of at least 3-6 months' duration. It has major impacts on individuals and society. There are both structural and idiopathic causes. Whereas CPP is not curable in many cases, it is treatable. The most promising approach is multidisciplinary patient-centered care including cause-directed therapy, lifestyle changes, talking therapies, meditation, acupuncture, and physiotherapy (this is not a complete list). One of the most common structural causes for CPP is endometriosis. This review investigates current scientific concepts and recent innovations in this field as well as for CPP in general

Anxiety‐related factors associated with symptom severity in irritable bowel syndrome

Background Gastrointestinal symptom‐specific anxiety and somatization have both been associated with higher symptom severity in patients with irritable bowel syndrome (IBS); however, this relationship has not been explored fully. Moreover, the performance of the visceral sensitivity index (VSI) for measuring gastrointestinal symptom‐specific anxiety has not been examined in a UK population. We conducted a cross‐sectional survey to examine these issues. Methods Gastrointestinal symptom‐specific anxiety was measured using the VSI, and somatization was measured via the patient health questionnaire‐12 (PHQ‐12) in adults from the UK community with Rome IV‐defined IBS. Exploratory factor analysis was performed on the VSI, prior to subsequent analyses, to establish its factor structure. Multiple regression analysis was used to determine the relationship between demographic features, different factors of the VSI, somatization, and IBS symptom severity. Key Results A total of 811 individuals with IBS provided complete data. Factor analysis of the VSI revealed a three‐factor structure, accounting for 47% of the variance. The first of these VSI factors and the PHQ‐12 were both strongly and independently associated with IBS symptom severity, for the group as a whole and for all four IBS subtypes. Most VSI items concerned with overt gastrointestinal symptom‐specific anxiety loaded onto the other two VSI factors that were not associated with symptom severity. Conclusions and Inferences The factor structure of the VSI requires further investigation. Our findings cast doubt on the central role of gastrointestinal symptom‐specific anxiety as a driver for symptom severity in IBS. Awareness of both gastrointestinal and extra‐intestinal symptoms, however, is strongly associated with symptom severity